Affordable Access

Publisher Website

Combining Yttrium 90–Labeled Ibritumomab Tiuxetan with High-Dose Chemotherapy and Stem Cell Support in Patients with Relapsed Non-Hodgkin's Lymphoma

Authors
Journal
Clinical Lymphoma
1526-9655
Publisher
Elsevier - CIG Media Group LP
Volume
5
Identifiers
DOI: 10.3816/clm.2004.s.005
Keywords
  • Autologous Stem Cell Transplantation
  • Radioimmunotherapy
  • Targeted Therapy
Disciplines
  • Medicine

Abstract

Abstract Targeted radioimmunotherapy, including yttrium 90–labeled ibritumomab tiuxetan (Zevalin®) and iodine I 131 tositumomab (Bexxar®), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing autologous hematopoietic stem cell transplantation. The results of phase I and II trials suggest that radioimmunoconjugates can be safely combined with high-dose chemotherapy, although the optimal approach remains to be established. This review focuses on the use of90Y ibritumomab tiuxetan combined with high-dose chemotherapy in the setting of autologous hematopoietic stem cell transplantation.

There are no comments yet on this publication. Be the first to share your thoughts.